Physician profile
Amber Boyle
NPI 1245089408
$1,878.08
in general payments reported to CMS, 2019-2025
14 companies · $1,878 in 2025
The $1,878 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $511.04 | 2025 | |
| Janssen Biotech, INC. | $288.19 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $233.62 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $201.80 | 2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $165.30 | 2025 | Rezdiffra |
| Novo Nordisk INC | $161.00 | 2025 | Wegovy |
| Ardelyx, INC. | $107.38 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.25 | 2025 | Xifaxan |
| Pfizer INC. | $53.92 | 2025 | |
| Qol Medical, LLC | $31.74 | 2025 | Sucraid |
| Celltrion USA INC. | $16.95 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $16.56 | 2025 | Sutab, Suflave |
| Digestive Care, INC. | $15.88 | 2025 | Pertzye |
| Phathom Pharmaceuticals, INC. | $8.45 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.